Scilex Holding Company Proceeds from Secured Notes Payable
Scilex Holding Company (SCLX) reported Proceeds from Secured Notes Payable of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromSecuredNotesPayable · last filed 2024-03-12
- Scilex Holding Company proceeds from secured notes payable for the quarter ending 2023-12-31 was $0.00.
- Scilex Holding Company proceeds from secured notes payable for the quarter ending 2023-09-30 was $0.00.
- Scilex Holding Company proceeds from secured notes payable for the quarter ending 2023-06-30 was $0.00.
- Scilex Holding Company proceeds from secured notes payable for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Scilex Holding Company proceeds from secured notes payable for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Scilex Holding Company proceeds from secured notes payable for fiscal 2022 was $62.50M, a 325.17% increase from fiscal 2021.
- Scilex Holding Company proceeds from secured notes payable for fiscal 2021 was $14.70M, a 42.72% increase from fiscal 2020.
- Scilex Holding Company proceeds from secured notes payable for fiscal 2020 was $10.30M.
| Period end | Proceeds from Secured Notes Payable 3 month | Proceeds from Secured Notes Payable 6 month | Proceeds from Secured Notes Payable 9 month | Proceeds from Secured Notes Payable 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $0.00 derived: sum of 2 quarters · filed 2024-03-12 | $0.00 derived: sum of 3 quarters · filed 2024-03-12 | $0.00 10-K · filed 2024-03-12 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | $0.00 derived: sum of 4 quarters · filed 2024-03-12 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $0.00 10-Q · filed 2023-08-11 | $0.00 derived: sum of 3 quarters · filed 2024-03-12 | $0.00 derived: sum of 4 quarters · filed 2024-03-12 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-12 | $0.00 derived: sum of 2 quarters · filed 2024-03-12 | $0.00 derived: sum of 3 quarters · filed 2024-03-12 | $0.00 derived: sum of 4 quarters · filed 2024-03-12 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $0.00 derived: sum of 2 quarters · filed 2024-03-12 | $0.00 derived: sum of 3 quarters · filed 2024-03-12 | $62.50M 10-K · filed 2024-03-12 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $62.50M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $62.50M 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $62.50M 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $14.70M 10-K · filed 2024-03-12 | |||
| 2020-12-31 | $10.30M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |